Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI-557 · 2 trials · 2 indications
The occurrence of AEs and SAEs
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| MEDI-557 low-dose | ACTIVE_COMPARATOR | - |
| MEDI-557 high-dose | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | Single IV dose of 0.3 mg/kg MEDI-557 |
| 2 | EXPERIMENTAL | Single IV dose of 3 mg/kg MEDI-557 |
| 3 | EXPERIMENTAL | Single IV dose of 15 mg/kg MEDI-557 |
| 4 | EXPERIMENTAL | Single IV dose of 30 mg/kg MEDI-557 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| MEDI-557 | DRUG | MEDI-557 low-dose |
Inclusion Criteria: * 18-45 years * written informed consent obtained from subject prior to performing any protocol related procedures * healthy by medical history and physical exam * females of child-bearing potential must use 2 effective methods of birth control for 14 days prior to 1st dose and ...
MEDI-557 is an investigational monoclonal antibody being studied for use in healthy adults and in respiratory syncytial virus (RSV). It is in Phase 1 clinical development and is not yet approved by the FDA.
MEDI-557 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN.
MEDI-557 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any use.
MEDI-557 has been studied in two completed Phase 1 clinical trials: NCT00578682, a dose escalation study in healthy adults, and NCT01562938, a study in adults with respiratory syncytial virus. Both trials were conducted in the United States.
MEDI-557 is a distinct investigational monoclonal antibody developed by AstraZeneca. No alternative names for MEDI-557 have been reported.